Shares of Baudax Bio BXRX rose 0.1% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 87.79% year over year to ($0.21), which missed the estimate of ($0.20).
Revenue of $201,000 declined by 42.41% year over year, which missed the estimate of $470,000.
Guidance
Baudax Bio hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Aug 05, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/uncpck7j
Price Action
Company's 52-week high was at $3.94
Company's 52-week low was at $0.57
Price action over last quarter: down 27.59%
Company Overview
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs, and a related proprietary chemical reversal agent and Dex-IN.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
